Expect Hybrid Design Concept/Performance Standards For NGS Regulatory Framework
This article was originally published in The Gray Sheet
Participants at a recent FDA workshop next-generation sequencing diagnostics mulled the differences between design concept and performance standards to govern development of NGS tests, with many agreeing that a hybrid approach was necessary.
You may also be interested in...
A new proposed framework to realize President Obama's Precision Medicine Initiative has significant potential for device and diagnostic companies, according to NIH Director Francis Collins. He says it will give them a "competitive opportunity" to develop cheaper whole genome sequencing tests and open the door to other exciting technologies.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.